vascular endothelial growth factor Clinical Research Trials

Please select a valid location from the dropdown

Found 185 clinical trials

featured

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.

We are currently recruiting participants for a clinical research study to evaluate the efficacy of an investigational medication in adults with Diabetic Kidney Disease.

hemoglobin a1c

kidney function tests

diabetic chronic kidney disease

diabetes

diabetic complication

12 views
14 Jan, 2021
1 location

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted

2 views
05 Dec, 2020
67 locations

Activity Study of Bevacizumab With Temozolomide Irinotecan for Neuroblastoma in Children

questions: does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used

refractory neuroblastoma

monoclonal antibodies

dinutuximab

topotecan

high-risk neuroblastoma

57 views
30 Mar, 2020
10 locations

Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma

effect on vascular endothelial growth factor and CD 133.

0 views
01 Mar, 2020
1 location

25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti

bevacizumab

visual loss

detachment

adjuvant therapy

retinopathy

5 views
08 Nov, 2020
1 location

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2VEGFR-2, Induces Transporter Pgp function in vitro. This study in patients with advanced cancer

solid tumour

advanced cancer

growth factor

cancer

0 views
29 Mar, 2020
1 location

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the

neutrophil count

growth factor

solid tumor

mitomycin

0 views
07 Nov, 2020
1 location

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2VEGFRFGFRfibroblast growth factor receptor

epidermal growth factor

lung cancer

measurable disease

ct scan

g-csf

0 views
13 Apr, 2020
6 locations

Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more

0 views
08 Jul, 2019
1 location

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP

bevacizumab

vascular endothelial growth factor

antiangiogenic therapy

vegf

blindness

4 views
07 Nov, 2020
1 location

Filter By

Found 185 clinical trials